Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I lost moderator status on several pages, probably due to infrequency of posting. They did not replace you, so do you just miss the extra (if any) work? It's really not a big deal.
I agree with Citrati, as I am both there and here in $SYN. Both have great potential and broad product lines in development. Not one-trick ponies.
Now you sound like you're playing with a pair of dice. Buy papa a new pair of shoes. lol
...and continuing to go up at the moment. $10.45 when I started typing.
Edit: now 10.30
cool publicity. maybe that's what drove our price up.
Clearly aimed at those who are nostalgic for the band and at least some publicity for Jeffersons; not much profit in the one barrel. Now, all we need is for a more popular group, the Eagles for instance, to pick out a few barrels, maybe rock and roll them around and - voila - Eagles rock and roll bourbon.
Max,
And the one in the top twenty was the "cheapie," available for under $30!
Have they ever put out their favorite top, top, top bourbons? I have to admit my looking at their stories is sporadic, so I mostly pay attention in the context of my investment in $ROX.
Steve
Bourbon Reviews Favorite bourbons around $30 article (hint: Jefferson's very small batch makes the list):
http://gobourbon.com/top-20-bourbons-around-30/?utm_source=Bourbon+Review+-+Master+Email+List&utm_campaign=4d9f922d2b-September_2013_Newsletter9_24_2013&utm_medium=email&utm_term=0_f138702ad8-4d9f922d2b-78826077&mc_cid=4d9f922d2b&mc_eid=ce3fa7b4cc
Fern,
I don't believe it's simply a pump and dump, but I'm not sure how much of anything is going on. Certainly no promotion. As there are only 100 messages on this board, you might just read them in 10 minutes or less. The NNAB website will also tell you a bit, and it's not long on specifics, but it may link to their 10k and 10q.
There is also some history on NNAB mentioned in many posts over on the Cellceutix board, most recently about 4-6 days ago. The Honchos at Cellceutix, Leo Ehrlich and Krishna Menon, are the fathers of the two NNAB principals and also own part of the stock. Speculation is that the "boys" alerted the dads to the availability of the Polymedix assets in bankruptcy court. The dads acquired the assets for cheap on a stalking horse bid and now one of those drugs was accelerated, completed Phase 2b and has propelled that stock higher. Some speculate NNAB was the kids reward, but I think that's false and the timing was way off.
If you find anything good, please report back. Did this show up on one of your stock screens?
Steve
That was a very nice first post! Thank you for sharing.
Yes, IHub has a Prolor/PBTH board, even though the business was subsumed into OPK. Links to DD should still be there. I was in both stocks, so it wasn't so bad for me, but many PBTH shareholders (myself included) felt Prolor had a brighter future by itself.
Yes. A valid reason for why Dr Frost has not been purchasing shares on the open market.
Not only are there other items OPK has which they have issued PRs on, there are many other items that the Prolor platform can be used on. The HGH product has been licensed, but there is also the extended life hemophilia drug, for one.
No to mention also redeploying some resources toward the autism drug or the other polycidins. If their IP has been patented, those also have finite timelines by which they have to reach marketability.
I am patient. My cost range is $4-5 per share. The Doctor will deliver, IMHO.
Yes, I was in Prolor and took $OPK shares in exchange, but also was in $OPK even before that. It would be nice to have a really good important announcement.
Ask him when he is buying more $OPK and his other stocks.
Yup.
That explains the gap. $OPK was VERY strong during that period, always over $10/sh. About 12/12 or so, it dropped off that plateau. Had I been the good doctor, I would have been very happy at the value of my $OPK portfolio and would not have used my cash either.
EDIT: I used my Fidelity chart to track prices day by day during the period.
OK. Thank you for checking.
What was the period he missed buying $OPK for a month? It could also have been when the price had surged.
You mean the 914?
Did that gap in his buying $OPK coincide with any major event?
I don't know. I doubt that the change at TEVA affected Dr. Frost's buying of $OPK, other than possibly being depressed at being rejected. I really doubt that.
If you look at:
http://www.secform4.com/insider-trading/898860.htm
you will see his latest insider stock buys (at least thru Frost Gamma Investments) across the board. He was not using tons of cash other than in OPK recently, so perhaps he is concentrating on making a major philanthropic gift or is in a 30-day quiet period (I hope) preceding a major announcement at OPK.
The election of the new Chairman was several weeks ago and coincided with the pop in PPS.
Looks like exercise of a purchase option and sale of just enough shares to pay the taxes and get some money out for holiday shopping. Did not sell all shares acquired.
Any of your thoughts on the general market you care to share are welcome to these old eyes.
Agreed. I think Leo proved he had "a pair" when he pulled of the Polyheist. He should be tough enough in negotiations to license or sell any of our products.
Yes, the old "pride goeth before a fall."
GO $CTIX
Yes, I hold the first one. I believe several of us hold at least one other Frost stock. Looking at his holdings is how I came here to $ROX.
Larry Smith posted this on his blog:
" Possible Impact of Merck Acqusition of Cubist on the Trius CVR
Posted by Larry Smith on Dec 8, 2014 • (0)
I was just asked about the potential impact on the value of the Trius CVR of the Merck acquisition of Cubist. You may recall that when Trius was acquired, Trius shareholders received $1.00 for each share that they tendered. If Syvestro (tedizolid) sales in the US, Europe and Canada reach $125 million in 2016 we get $1.00 and we get $2.00 if they meet or exceed $135 million. In between the payment is pro rata for each $1 million of sales so that at $126 million we will get $1.10, at 127 million $1.20 and so on. The CVRs are non-tradable following the acquisition. This feature means that they will be subject to the capital gains rate rather than ordinary income if and when they are paid.
Whatever Trius could have done on its own, there is no question that the already in place robust sales and marketing infrastructures of Cubist will bolster sales. The same could be said in regard to the impact that Merck will have relative to Cubist. Merck has a powerful marketing organization outside of the US while Cubist gets almost all of its sales in the US. Merck also has long experience in hospital infectious disease marketing through marketing the carbipenem antibiotic Primaxin and the anti-fungal agent Cancidas.
My estimate for 2016 sales was $137 million as of my last report on Trius. I have not been following Cubist closely. However, I note that one Wall Street analyst whom I respect recently put out a note with estimates for Syvextro (tedizolid) of $12 million in 2014, $67 million in 2015 and $122 million in 2016. Let’s hope that Merck can nudge Syvextro over the $135 million milestone in 2016. Aaaah, the good old days."
http://smithonstocks.com/possible-impact-of-merck-acqusition-of-cubist-on-the-trius-cvr/
New WSJ article on Bourbon shortage in general.
Fear of a Bourbon Shortage Puts Enthusiasts Over a Barrel
/The Wall Street Journal
By
Tripp Mickle
December 8, 2014
SIMPSONVILLE, S.C.—On a recent Saturday, Edward Johnson hurried into Harvard’s Liquor & Wine and made a beeline toward a 4-foot-wide section of bourbon. There he bypassed the Old Crow and Jim Beam and reached up to grab one of four stubby bottles of Blanton’s, a rye bourbon. At the register, the cashier had a 10-year-old bottle of Henry McKenna Single Barrel waiting for him. It was set aside that morning.
Mr. Johnson shelled out $107 for the bourbon and then headed to a nearby Sam’s Club, where he spent about $100 on diapers for his 19-month-old daughter. People observing this routine might wonder if he has a drinking problem. He doesn’t. What he has is a serious case of anxiety.
It began two years ago, when Mr. Johnson and his brother-in-law heard of an alleged bourbon shortage. He has been making monthly liquor and diaper runs ever since.
“It scared us and fear is a motivating factor,” said Mr. Johnson, a 36-year-old managing partner of Old Colony Furniture, who now has a stash of about 50 bottles of bourbon. The collection, he says, grew out of an urge to make sure there would never be a time “I wanted bourbon and couldn’t get it.” After a while, he says, the habit “took on a life of its own.”
He isn’t alone. Panic has gripped bourbon enthusiasts across the country, and they are amassing stockpiles of it, hoping to guard against shortages and price hikes.
Greg Gilbert of Lovettsville, Va., built a basement bunker for his 700 bottles of bourbon. He also joined a private club so he could bypass retailers and buy barrels straight from distillers. Joe Conner, a warehouse worker from Rockford, Ill., created a spreadsheet for his 120 bottles of bourbon so he could keep track of what he had bought, what he had opened and what he needed to purchase.
Related Video
Hoping to protect themselves from shortages and rising prices, bourbon hoarders are stocking up. WSJ's Tripp Mickle and Simon Constable discuss. Photo: Getty
Steffen Braüner, a surveyor from Denmark, travels to Las Vegas for a whiskey-tasting event so he can embark on an annual bourbon hunt.
Last year, he drove from Las Vegas to Utah, hoping that in a state filled with teetotalers he would be able to find a bottle of the extremely limited George T. Stagg. “There’s much less of what’s good to buy,” says Mr. Braüner, who returned to Denmark empty-handed.
Bourbon’s popularity has surged ever since the amber liquor became a star of Mad Men. Magazines such as GQ and Bon Appétit have devoted pages to articles on bourbon cocktails. The Manhattan and Old Fashioned have become fashionable again. President Barack Obama recently proposed a “Bourbon Summit” with Kentucky Senator Mitch McConnell.
“Whiskey has gone away from being seen as an old man drink,” says Mahesh Patel, a structural engineer who owns 4,000 bottles of whiskey and sponsors an annual tasting conference in Las Vegas.
Sales of bourbon are growing at a dizzying rate. Domestic sales of Kentucky-made bourbon have increased 36% in the last five years to $1.5 billion. Exports rose 56% to $300 million from 2010, according to the Distilled Spirits Council of the U.S.
All this makes bourbon aficionados practically see double. Prices of their favorite brands are rising. Within a few months, Mr. Johnson says he saw the price of a bottle of his favorite Blanton’s go from $45 to $60.
Rationing is increasing. Buffalo Trace Distillery, in Frankfort, Ky., has hired an allocation manager to make sure its bourbon is distributed evenly nationwide. Willett Distillery, in Bardstown, Ky., this year began rationing the amount of whiskey it sent wholesalers for the first time since prohibition ended in 1933.
Anxiety has intensified since Japan-based Suntory paid $13.5 billion in January for Beam Inc., the maker of Jim Beam, Knob Creek and Maker’s Mark bourbons. A main reason for the acquisition was to export whiskey—and a taste for American-made bourbon.
Bourbon made today can’t be sold tomorrow. It typically ages a minimum of four years in oak barrels charred by fire. The more it ages, the richer its flavor. Also, it evaporates over time. One of the oldest bourbons on the market, Pappy Van Winkle 23 Year Old, begins as a 53-gallon barrel but yields just 14 gallons. A bottle sells for about $250.
It isn’t bourbons like Jim Beam and Evan Williams —the kind often served at parties and tailgates—that are in short supply. Those are produced in much larger quantities, but people are increasingly buying bourbons that are produced in smaller batches, the Distilled Spirits Council says. That is why bottles of Elmer T. Lee, which its producer says smells of clover and old leather, and John E. Fitzgerald Larceny, which its maker says tastes of buttery caramel and honey, are tough to find.
Some suspect distillers are fueling the frenzy—only to capitalize on it. Reid Bechtle, a retiree with more than 500 bottles of bourbon, became suspicious in 2010 when Heaven Hill discontinued its Elijah Craig 18-Year-Old Single Barrel bourbon priced at $39 but later released 21- and 23-year-old versions of Elijah Craig priced at $120 and $200, respectively. Mr. Bechtle wondered if Heaven Hill intentionally pulled its 18-year bourbon off the market to age it three to five years longer so it could command a higher price.
A Heaven Hill spokesman said it had a supply problem that year and felt the bourbon was underpriced. The company plans to reissue Elijah Craig 18-Year-Old next year but will charge more than $39 a bottle.
Bourbon makers manage supplies closely. They have been burned by having too much whiskey in the past, says Buffalo Trace CEO Mark Brown. During the 1970s, the industry ramped up production only to have demand crash. Bourbon makers then put it on the market at lower prices. It took decades to recover.
“A whiskey maker’s worst nightmare is having too much,” Mr. Brown says.
It is this kind of thing that compels Mr. Gilbert to keep stockpiling. His basement is filled with bourbons that have spiked in price or are no longer available. W.L. Weller Centennial: “Disappeared.” Old Charter 12-Year: “Gone.” Eagle Rare Ten, 101 Proof: “Discontinued,” he says.
His wife, Kelly, says she sometimes wanders downstairs, surveys the ever-growing tower of bourbon, and thinks: “If he sold that, think of all the shopping I could do.”
Write to Tripp Mickle at Tripp.Mickle@wsj.com
Corrections & Amplifications
Blanton’s is a rye bourbon. An earlier version of this article incorrectly described it as a wheat bourbon.
http://www.wsj.com/articles/fear-of-a-bourbon-shortage-puts-enthusiasts-over-a-barrel-1418004595?mod=djem10point
BTW, OT: I have a 1917-bottled bottle of Old Charter sitting and waiting.
I'd be happy with Monday morning as well.
That would be good.
Max, I agree that Okaly should provide his reasoning - by some sort of analysis - or it sounds like spreading FUD to me. Steve
Al,
I think much of the share price decline is due to (a) relatively opaque information about the company, and (b) the reliance on existing sales to Russia and thru entities in China. I know many of their scientists are from FSU states and you take your collaborations where you can get them but...
That said, are we aware of how the patent infringement suit is going?
Steve
long and not about to sell
CERN News
Zecotek's LFS-3 Scintillation Crystal Plates Successfully Tested for Final Qualification for Hadron Collider Experiments at CERN
CNW Group
Zecotek Photonics Inc. 1 hour ago
SINGAPORE , Dec. 1, 2014 /CNW/ - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I.F), a developer of leading-edge photonics technologies for industrial, healthcare and scientific markets, today announced that the previously announced new configuration of LFS scintillation crystals (LFS-3 plates) have been successfully assessed by CERN scientists of the Large Hadron Collider using the high energy beam upgrade. Due to the positive results, the scientific team at CERN has ordered additional LFS-3 plates to be integrated into modules for the main Compact Muon Solenoid (CMS) experiment. The Company was informed by the CERN group that the details of a qualification contract and supply agreement will be finalized in early 2015.
"We are excited about the progress taking place at CERN and look forward to the opportunity to have our newly configured LFS technology used in CERN`s upgrade Large Hadron Collider," said Dr. A.F. Zerrouk , Chairman, President, and CEO of Zecotek Photonics Inc. "Our new LFS plates with their new design, unique and unmatched cost performance advantages fulfill the principle criteria necessary for higher energies to be generated in the new LHC upgrades and CMS experiments. We are working with our strategic partner BOET and other associates to finalize the logistic and economic requirements to meet the contractual requirements anticipated in early 2015."
The CMS Experiment is one of two large general-purpose particle physics detectors built on the Large Hadron Collider at CERN in Europe . It is composed of three main components: scintillation material, photo-detectors and the ubiquitous electronic system. Zecotek's new LFS-3 plates were originally tested for use in CERN`s high energy experiments because of their density of material, stopping power, fast decay time, very good energy resolution, unique radiation hardness, and competitive effective price.
In March 2013 , CERN scientists confirmed that a new subatomic particle discovered at the world's most powerful particle accelerator is the Higgs Boson. As CERN pushes into this new frontier of science, additional experiments are required to determine the particle's properties and its true form. High-energy scintillation crystals with high radiation hardness and solid-state photo detectors are paramount for the success of the next stage of experiments.
http://finance.yahoo.com/news/zecoteks-lfs-3-scintillation-crystal-140000872.html
TOB, You do a lot more than I. Have to contribute what I can. Steve
The link does not work unless you have a Barrons subscription. However, someone else posted the whole article, which generally is about Frost's investments but does not mention ROX.
At the risk of it being deleted ($oldier, I understand if you feel the need to do so), here is the text:
UP AND DOWN WALL STREET ( http://online.barrons.com/articles/why-etfs-beat-money-managers-1417235993 )
Stockpickers’ Blues
A leading market analyst finds that no particular style of stock selection is long successful in the current market.
By BILL ALPERT ( http://online.barrons.com/public/search/results.html?KEYWORDS=%22BILL%20ALPERT%22&ARTICLESEARCHQUERY_PARSER=bylineOR )
November 29, 2014
Wall Street has gone passivist.
A few hedge-fund activists, including Pershing Square’s Bill Ackman, are having a good year, but less than 15% of the money managers who actively select stocks are ahead of their benchmarks. Active mutual funds actually lost money in the September quarter, on average.
Even at this tabloid devoted to stock-picking, the active voice has become harder to find. Sitting on our levee, we can only watch as rivers of money flow to passive investment vehicles and strategies, such as exchange-traded funds and smart beta. Back in my school days, I wanted skills to help me create jobs and grow the economy. So I took English courses. The instructors tried to teach me to build active, clear sentences and spurn the passive voice. Instead of writing “Twitter was overloved,” I learned to recycle Shakespeare and write, “Wall Street loved the stock not wisely, but too well.” With passivism’s triumph, all my practical skills have become moot.
Quantitative managers have done better this year than active investors following the ancient ways. That gives us yet another good reason to listen to Nomura’s quant strategist, Joe Mezrich, as he analyzes active investing’s malaise. In this stock market’s five-year rise, Joe notes that the returns of any one stock have had a low correlation with those of another stock. That would seem to favor stockpickers. Unfortunately, the spread of returns has also been small, which limits the rewards of successful stock selection.
“Managers may be smart enough to pick the right stock,” Mezrich told me, “but the returns are not there.” Ten years ago, a money manager might have levered up to boost returns in a low-volatility environment. But now, leverage is a dirty word. Instead, a lot of active managers seem to have hopped aboard momentum stocks, that is, whichever stocks have risen steadily in prior months. The momentum strategy worked well until March and April, when such stocks got crushed. Mezrich is a close student of investment strategies, and he’s found that no particular style of stock selection is successful for long in the current market; leadership keeps flipping from momentum to value to market-cap stocks, and beyond.
And the market has been even more fickle in rewarding investors for selecting industry sectors, he notes. Utility stocks started the year strongly, for example, then floundered in the summer. Telecom stocks started weak, then rebounded. When Mezrich looked at the stock performance of the market’s 10 broad industry sectors, as defined by the Global Industry Classification Standard of index firms MSCI and Standard & Poor’s, he found that industry leadership has been reversing from month-to-month at a rate unseen in decades of stock-market history. “Even if you’re picking the right stocks in a sector,” he says, “things are moving around so much that your performance doesn’t persist.”
Whatever the explanation–or excuse–for the average active investors’ underperformance, how can you blame a pension fund or endowment for wondering if they’ve been overpaying their active stockpickers?
History is being made. Wall Street’s propensity toward passivism gives it a rare chance to set a good example. If only the rest of our troubled world would follow suit.
While many professional investors look like overpaid clods this year, the stock market’s steady ramp-up has left a lot of people feeling like geniuses. Yet we live among market participants who indisputably are geniuses—for example, Stanford’s Nobel Prize-winning biochemistry professor Roger Kornberg and his financial backer Phillip Frost, a famous drug-industry entrepreneur whose name adorns South Florida schools and museums. One wondrous aspect of their joint venture is that it involves a 54-cent penny stock, by the name of Cocrystal Pharma ( http://quotes.barrons.com/COCP ) (ticker: COCP).
Kornberg won the Nobel in 2006 -- 47 years after his father got one -- for elucidating the roundabout process that our genes use to implement their instructions. That same year, Frost became a billionaire with the $8 billion sale of his company, IVAX, to generic-drug giant Teva Pharmaceutical Industries ( http://quotes.barrons.com/TEVA ) (TEVA). A few months ago, Frost said he would step down as Teva’s director and board chairman at year end.
Frost’s retirement will give him more time to attend to his many other businesses, like the little investment bank Ladenberg Thalmann Financial Services ( http://quotes.barrons.com/LTS ) (LTS) and Opko Health ( http://quotes.barrons.com/OPK ) (OPK), a collection of development-stage medical projects about which I wrote skeptically a couple of years back, when Opko shares were at $4.18 and its market cap, about $1.25 billion (“Sweating Out the Results of a Blood Test, ( http://online.barrons.com/articles/SB50001424053111904414004578016371446586746 ) ” Oct. 1, 2012). Opko’s sales and losses have since increased, but its shares have doubled, to $8.38.
Frost recently told me that he met Kornberg when the Stanford scientist signed on as a Teva scientific advisor. They formed Cocrystal Discovery in 2008. “Roger told me about a technology idea he had to create new antiviral drugs,” Frost related. “He asked if I’d be interested. So we started Cocrystal.”
Frost and Opko put up seed money. Then, in 2011, Teva chipped in $7.5 million to fund Cocrystal’s development of Hepatitis C drugs, with options to invest another $37.5 million as time went by. By the end of last year, however, most of Teva’s options had expired unexercised, and the privately held Cocrystal was down to its last million bucks of cash.
So, in January 2014, the little company came public through a process just slightly less convoluted than genetic transcription, known in the penny-stock trade as a reverse merger: Kornberg’s brainchild merged itself into a publicly held shell company partly controlled by Frost and Opko, called Biozone Pharmaceuticals. The renamed Cocrystal Pharma bolstered its balance sheet with some cash from investors, while exchanging Biozone’s old operations for stock in another Frost-financed outfit called MusclePharm ( http://quotes.barrons.com/MSLP ) (MSLP), which sells nutritional supplements to jocks and bodybuilders.
Cocrystal has remained in penny-stock purgatory all year, sliding in over-the-counter trading from around 75 cents to 25 cents, before perking up in October to reach last week’s level near 50 cents, and a market cap that was all of $60 million. Then, on Monday, Cocrystal said it was merging again.
This time, the Frost and Kornberg outfit is merging with a privately held company founded by Raymond Schinazi, an Emory University professor with a proven record of developing antiviral drugs and starting companies, such as Pharmasset, which Gilead Sciences ( http://quotes.barrons.com/GILD ) (GILD) acquired in 2012 for $11.4 billion. The merger announcement spent a lot of detail on the impressive pedigrees of these talented guys, but said practically nothing about the deal’s capital structure.
I don’t know about you, but I find myself wondering what all these giants of research and industry are doing in the penny-stock market.
I didn’t hear back from either Frost or Kornberg when I queried them on the topic. I was able to talk to two other substantial investors in Cocrystal and Opko, by the names of Barry Honig and Michael Brauser. Over the past few years, these two South Florida gents have invested alongside Frost in a couple of dozen micro-cap companies. Scanning the list of those companies last week, I calculated that their average market cap was about $75 million. The middle of the pack (in other words, the median company) had a valuation of under $30 million.
While Honig works out of Boca Raton, Brauser has his business in the same Biscayne Boulevard address in Miami as Opko Health and Frost’s own investment operation. Brauser calls Frost a mentor, but like Honig, Brauser says they make their investment decisions independently. “We’ve invested in a lot of the same deals,” Brauser tells me, “because we run in the same circles.”
Frost first invested with Brauser and Honig when they were running the Internet marketing company InterClick, which Yahoo! ( http://quotes.barrons.com/YHOO ) (YHOO) acquired in 2011 for $270 million. Their other ventures have ranged from mineral plays to biotech. As noted, they’re all small.
“A lot of the greatest entrepreneurs,” Brauser says, “have created wealth by starting small companies that became very large companies.”
Controversy has occasionally followed these fellows’ deals. The credit-reporting company Equifax ( http://quotes.barrons.com/EFX ) (EFX) bought an e-mail marketing business from Brauser in 2002 for $135 million, and the parties traded blame for its subsequent decline until settling their lawsuits some years later. A Biozone founder sued Brauser, Honig, and Frost after they became involved with the predecessor company of Cocrystal. The suit was settled, but the founder is fighting on in a California state court.
Companies that come public through reverse mergers tend to work out poorly for everyone except the insiders, but Brauser defended the technique as a way for a company’s founders to avoid the predation of big venture-capital financiers. In separate interviews, he and Honig reminded me that Berkshire Hathaway came public via a reverse-merger.
Penny stocks don’t deserve their bad rap, Honig says. “I’d rather invest in a penny stock going to a dollar,” he says, “than a dollar stock going to a penny.”
“Frost is probably one of the smartest men on the planet,” adds Honig. “This world needs a lot more people like him.”
Honig then challenged me to a pair trade. He’d go short Apple (AAPL) and long Opko -- a penny-stock promoter’s epic challenge to the mega-cap gods.
“You don’t bet against Phil Frost,” Honig says.
Has this video been posted here yet?
http://www.bnn.ca/Video/player.aspx?vid=496129
Thanks to slapa for posting within some SA comments.
Thank you for posting the article, Tom. EOM